Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-10-12

Clinical Trial Update: A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating dalteparin prophylaxis in high-risk ambulatory cancer patients was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FRAGMIN (DALTEPARIN SODIUM)

Snippet

Sponsor: University of Rochester | Conditions: Venous Thromboembolism, Pulmonary Embolism | Phase 3 | Status: TERMINATED | Results posted: 2015-10-12